Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Revtenon Dec 14, 2023 12:54pm
199 Views
Post# 35784828

RE:Question

RE:Question

IMHO

1. We get a decent Share Price Bump the day we hit 90. 

2. 30-60 days for Baxter to Review Data and while this is going on the Share Price has a continued gradual appreciation during the review. We shouldn't $1.00 or more...

3. Baxter obviously will move ahead with the Distribution Agreement with a Milestone Payment OR just decide to BUY it all and tie it all together with their Vantive IPO in the Spring or early Summer. BOOM! Share Price should have a Major Move at this point... March - April  time frame. 

4. Upon FDA Approval whether  it happens before or at 150 Patients we have a Hyper Extended Share Price Run that is usually way beyond actual value before it comes back to earth and settles at Industry Standard PE Values for this Medical Sector of the market. 

Will be very diligently watching for the Hyper Extended Days to Sell for massive gains.... but not all as nobody knows how high we can go!

I have personally witnessed many many stocks do these type of Massive Moves like for example TPST in October or ADTX in September. We would need to be on the Nasdaq (Vantive?) to experience it on our Holdings here. 

All IMHO of course. 

Looking Up!

Rev

<< Previous
Bullboard Posts
Next >>